Terns Pharmaceuticals Inc (TERN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Terns Pharmaceuticals Inc stock (TERN) is currently trading at $50.00. Terns Pharmaceuticals Inc PS ratio (Price-to-Sales) is 302.64. Analyst consensus price target for TERN is $58.11. WallStSmart rates TERN as Sell.
- TERN PE ratio analysis and historical PE chart
- TERN PS ratio (Price-to-Sales) history and trend
- TERN intrinsic value — DCF, Graham Number, EPV models
- TERN stock price prediction 2025 2026 2027 2028 2029 2030
- TERN fair value vs current price
- TERN insider transactions and insider buying
- Is TERN undervalued or overvalued?
- Terns Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- TERN Piotroski F-Score and Altman Z-Score
- TERN analyst price target and Smart Rating
Terns Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Terns Pharmaceuticals Inc (TERN) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Terns Pharmaceuticals Inc (TERN) Key Strengths (2)
118.97% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Terns Pharmaceuticals Inc (TERN) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 302.6x annual revenue
Very expensive at 18.6x book value
Supporting Valuation Data
Terns Pharmaceuticals Inc (TERN) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 8.5/10) while 3 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (302.64), Price/Book (18.60) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -29.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -29.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TERN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TERN's Price-to-Sales ratio of 302.64x trades at a deep discount to its historical average of 857.21x (7th percentile). The current valuation is 93% below its historical high of 4581.27x set in Feb 2026, and 74% above its historical low of 174.03x in Apr 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for Terns Pharmaceuticals Inc (TERN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Terns Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 151M in cash.
Spending 1992% of revenue (20M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -20M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Terns Pharmaceuticals Inc.
Bottom Line
Terns Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Terns Pharmaceuticals Inc(TERN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other chronic liver diseases. The company is headquartered in Foster City, California.